10x Genomics, Inc. (TXG) FY2026 Q2 P&L / Income Statement

10x Genomics, Inc. (TXG) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (6 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

151,036,000 US dollars

Cost of products and services revenue

38,539,000 US dollars

Gross profit

112,497,000 US dollars

Total operating expenses

132,052,000 US dollars

Income (loss) from operations

negative 19,555,000 US dollars

Total other income

910,000 US dollars

Income (loss) before provision for income taxes

negative 18,645,000 US dollars

Provision for (benefit from) income taxes

negative 714,000 US dollars

Net income (loss)

negative 17,931,000 US dollars

Services

10,681,000 US dollars

License and royalty revenue

1,942,000 US dollars

Single Cell

88,451,000 US dollars

Spatial

42,301,000 US dollars

Single Cell

3,087,000 US dollars

Spatial

4,574,000 US dollars

Research and development

56,791,000 US dollars

Gain on settlement

negative 3,400,000 US dollars

Selling, general and administrative

78,661,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.